MBA, Business Management
Stockholm School of Economics, Stockholm, Sweden
MSc, Biomedicine
Kalmar University, Kalmar, Sweden
RN, General Nursing
Lund University, Lund, Sweden
Ann-Louice Bruhn brings over 25 years of global and US biopharmaceutical leadership, shaping launch, market access, and pricing strategies across immunology, hematology, oncology, vaccines, and rare diseases. In her leadership role in integrated access and pricing within RTI-HS, she brings end-to-end biopharma experience. Drawing from her recent work in consulting and health technology, she builds integrated access, evidence, and pricing strategies that accelerate access; ensures global HTA readiness; and creates differentiated access stakeholder value that drives sustainable commercial impact.
Previously, she was a VP of US market access at a top 10 pharma company, leading the full portfolio of assets through launches and loss of exclusivity. She has led global market access and pricing, and global portfolio strategy for portfolios representing over $10B in value across immuno-oncology and hematology, in addition to roles in regional medical affairs, national business unit leadership, and clinical development.